Phase III Study of ASP2151 in Herpes Simplex Patients

Summary

To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.

Timeline

Start

2013-08

Primary completion

2015-04

Completion

2015-04-27

Outcome

Missed primary endpoint

registry NUMBER ASP2151: 66.4 Percentage of Participants NUMBER ASP2151 Placebo: 69.5 Percentage of Participants analysis (superiority test); ASP2151 vs ASP2151 Placebo; p = 0.5086 NCT01959295 ↗

Drugs

Indications